Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation

Journal of Cell Science
Claire L CopeSimon J Cook

Abstract

The mechanistic target of rapamycin (mTOR) protein kinase coordinates responses to nutrients and growth factors and is an anti-cancer drug target. To anticipate how cells will respond and adapt to chronic mTOR complex (mTORC)1 and mTORC2 inhibition, we have generated SW620 colon cancer cells with acquired resistance to the ATP-competitive mTOR kinase inhibitor AZD8055 (SW620:8055R). AZD8055 inhibited mTORC1 and mTORC2 signalling and caused a switch from cap-dependent to internal ribosome entry site (IRES)-dependent translation in parental SW620 cells. In contrast, SW620:8055R cells exhibited a loss of S6K signalling, an increase in expression of the eukaryotic translation initiation factor eIF4E and increased cap-dependent mRNA translation. As a result, the expression of CCND1 and MCL1, proteins encoded by eIF4E-sensitive and cap-dependent transcripts, was refractory to AZD8055 in SW620:8055R cells. RNAi-mediated knockdown of eIF4E reversed acquired resistance to AZD8055 in SW620:8055R cells; furthermore, increased expression of eIF4E was sufficient to reduce sensitivity to AZD8055 in a heterologous cell system. Finally, although the combination of MEK1/2 inhibitors with mTOR inhibitors is an attractive rational drug combinatio...Continue Reading

References

Mar 19, 2004·Nature·Hans-Guido WendelScott W Lowe
Apr 20, 2004·Oncogene·Yaël MamaneNahum Sonenberg
Apr 20, 2004·Oncogene·Arrigo De Benedetti, Jeremy R Graff
Jul 14, 2004·The Journal of Cell Biology·Laura S HarringtonRichard F Lamb
Feb 19, 2005·Science·D D SarbassovDavid M Sabatini
Apr 20, 2005·The Journal of Cell Biology·Biljana CuljkovicKatherine L B Borden
Jan 26, 2006·Cancer Genetics and Cytogenetics·Amber E AlsopPaul A W Edwards
Jul 10, 2007·Nucleic Acids Research·Hong JiangW Keith Miskimins
Dec 7, 2007·Genes & Development·Hans-Guido WendelScott W Lowe
Oct 29, 2008·Proceedings of the National Academy of Sciences of the United States of America·Andrew Y ChooJohn Blenis
Jan 20, 2009·The Journal of Biological Chemistry·Carson C ThoreenNathanael S Gray
Feb 13, 2009·PLoS Biology·Morris E FeldmanKevan M Shokat
Dec 4, 2009·Oncogene·S Menon, B D Manning
Aug 4, 2010·Proceedings of the National Academy of Sciences of the United States of America·Luc FuricNahum Sonenberg
Aug 4, 2010·Proceedings of the National Academy of Sciences of the United States of America·Takeshi UedaTak W Mak
Dec 16, 2010·Nature Reviews. Molecular Cell Biology·Roberto ZoncuDavid M Sabatini
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Aug 31, 2011·Proceedings of the National Academy of Sciences of the United States of America·Nina IlicThomas M Roberts
Nov 1, 2011·Nature Reviews. Drug Discovery·Don BenjaminMichael N Hall

❮ Previous
Next ❯

Citations

Mar 5, 2015·Proceedings of the National Academy of Sciences of the United States of America·Anthony C FaberJeffrey A Engelman
Jun 24, 2016·Translation·Regina Cencic, Jerry Pelletier
Jan 16, 2015·Cell Cycle·Masahiro MoritaIvan Topisirovic
Aug 22, 2015·Molecular Carcinogenesis·Oshrat Attar-SchneiderMichael Lishner
Apr 9, 2016·Seminars in Cell & Developmental Biology·Ruth NussinovPeter Csermely
Mar 7, 2015·Nature Reviews. Drug Discovery·Mamatha BhatIvan Topisirovic
Jun 21, 2016·Nature Communications·Yoshinori TsukumoNahum Sonenberg
Jul 12, 2016·Chemical Society Reviews·Shaoyong LuRuth Nussinov
Sep 16, 2016·Cell Cycle·Marta Markiewicz-Potoczny, David Lydall
Feb 2, 2017·British Journal of Haematology·Teresa Calimeri, Andrés J M Ferreri
Mar 9, 2018·International Journal of Molecular Sciences·Jessica Lawrence, Richard Nho
Feb 15, 2018·Cold Spring Harbor Perspectives in Biology·Jennifer Chu, Jerry Pelletier
Mar 11, 2018·Clinical Science·Alberto M MartelliJames A McCubrey
Mar 25, 2016·The EMBO Journal·Duygu Kuzuoğlu-ÖztürkElisa Izaurralde
Aug 26, 2017·Future Medicinal Chemistry·Ella LinehamSimon J Morley
Jul 7, 2019·Journal of Hematology & Oncology·Hui HuaYangfu Jiang
Jul 1, 2018·Cold Spring Harbor Perspectives in Biology·Nathaniel RobichaudRobert J Schneider
Jul 9, 2016·Expert Review of Proteomics·Ruth NussinovHyunbum Jang
Dec 23, 2016·Cellular and Molecular Life Sciences : CMLS·Jutta SteinbergerJerry Pelletier
May 11, 2019·Journal of Cellular Biochemistry·Asiya BatoolKhurshid I Andrabi
Nov 30, 2019·Molecular and Cellular Biochemistry·Asiya BatoolKhurshid Iqbal Andrabi
Nov 1, 2015·Biochemical Society Transactions·Nadeem Siddiqui, Nahum Sonenberg
Jul 12, 2017·Oncology Letters·Wei ZhuXing Yan Liu
Feb 27, 2016·Molecular Cancer Therapeutics·Suman MukhopadhyayDavid A Foster
Apr 11, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Johanna C BendellKathleen N Moore
May 31, 2018·Cancer Research·Katarzyna JastrzebskiLodewyk F A Wessels
Jan 17, 2015·Cancer Research·Jerry PelletierNahum Sonenberg
Nov 1, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hélène Malka-MahieuStéphan Vagner
Jan 15, 2021·Proceedings of the National Academy of Sciences of the United States of America·Cuiqing FanYi Zheng
Aug 7, 2021·Genes·Nikolay MehterovVictoria Sarafian
Jan 6, 2018·Organic Letters·Siva Sankar Murthy BandaruAnant R Kapdi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.